Michael Grissinger
Directeur/Membre du Conseil chez AKARI THERAPEUTICS, PLC
Fortune : 7 705 $ au 31/05/2024
Profil
Michael Grissinger is currently the Chairman at Kira Biotech Pty Ltd., Director at Atrin Pharmaceuticals LLC, Independent Director at Akari Therapeutics Plc, Independent Director at Aprea Therapeutics, Inc., Director at Atriva Therapeutics GmbH, and Director at Envisagenics, Inc. Previously, he served as an Independent Director at resTORbio, Inc., Director at Atrin Pharmaceuticals, Inc., Member-Management Board at Janssen Pharmaceuticals, Inc., and VP & Head-Pharmaceutical Corporate Development at Johnson & Johnson.
He holds an undergraduate degree from Juniata College and an MBA from Fox School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
APREA THERAPEUTICS, INC.
0,03% | 20/06/2024 | 1 844 ( 0,03% ) | 7 505 $ | 30/06/2024 |
AKARI THERAPEUTICS PLC
0,09% | 28/06/2024 | 20 000 000 ( 0,09% ) | 200 $ | 31/05/2024 |
Postes actifs de Michael Grissinger
| Sociétés | Poste | Début |
|---|---|---|
| AKARI THERAPEUTICS, PLC | Directeur/Membre du Conseil | 23/01/2018 |
| APREA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/05/2022 |
Atrin Pharmaceuticals LLC
 Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | Directeur/Membre du Conseil | 01/11/2018 |
Kira Biotech Pty Ltd.
 Kira Biotech Pty Ltd. BiotechnologyHealth Technology Kira Biotech Pty Ltd. operates as biotechnology company which develops novel immunomodulatory compounds for the treatment of immune system disorders. The company was founded by Georgina Clark is headquartered in Brisbane, Australia. | Président | 30/07/2020 |
Atriva Therapeutics GmbH
 Atriva Therapeutics GmbH BiotechnologyHealth Technology Atriva Therapeutics GmbH is a biopharmaceutical company that develops host-targeting antiviral therapies. It focuses on the development of new antiviral therapies against different respiratory viral infections. The company was founded by Rainer Lichtenberger and Henrik Luer Lueßen in April 2015 and is headquartered in Tuebingen, Germany. | Directeur/Membre du Conseil | 01/12/2020 |
Envisagenics, Inc.
 Envisagenics, Inc. BiotechnologyHealth Technology Envisagenics, Inc. engages in developing of artificial intelligence platform for discovering drugs. The company was founded by Maria Luisa Pineda and Martin Akerman and is headquartered in New York, NY. | Directeur/Membre du Conseil | - |
Anciens postes connus de Michael Grissinger
| Sociétés | Poste | Fin |
|---|---|---|
| ADICET BIO, INC. | Directeur/Membre du Conseil | 15/09/2020 |
| JOHNSON & JOHNSON | Corporate Officer/Principal | 01/01/2018 |
Atrin Pharmaceuticals, Inc.
 Atrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2012, Atrin Pharmaceuticals, Inc. is a DNA Damage Response development company that focuses on a pipeline of products resulting from a series of novel conformationally restricted macrocyclic molecules. Part of Aprea Therapeutics, Inc., the company is based in Doylestown, PA. Atrin Pharmaceuticals was acquired by Aprea Therapeutics, Inc. on May 16, 2022 for $1.33 million. The company's products have the highest known potency for inhibiting ATR and exhibit ATR selectivity with potential broad therapeutic profile. | Directeur/Membre du Conseil | - |
| ░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Michael Grissinger
| Juniata College | Undergraduate Degree |
| Fox School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| AKARI THERAPEUTICS, PLC | Health Technology |
| APREA THERAPEUTICS, INC. | Health Technology |
| JOHNSON & JOHNSON | Health Technology |
| Entreprise privées | 7 |
|---|---|
Janssen Pharmaceuticals, Inc.
 Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Health Technology |
resTORbio, Inc.
 resTORbio, Inc. BiotechnologyHealth Technology resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA. | Health Technology |
Atrin Pharmaceuticals LLC
Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | Health Technology |
Kira Biotech Pty Ltd.
Kira Biotech Pty Ltd. BiotechnologyHealth Technology Kira Biotech Pty Ltd. operates as biotechnology company which develops novel immunomodulatory compounds for the treatment of immune system disorders. The company was founded by Georgina Clark is headquartered in Brisbane, Australia. | Health Technology |
Atrin Pharmaceuticals, Inc.
Atrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2012, Atrin Pharmaceuticals, Inc. is a DNA Damage Response development company that focuses on a pipeline of products resulting from a series of novel conformationally restricted macrocyclic molecules. Part of Aprea Therapeutics, Inc., the company is based in Doylestown, PA. Atrin Pharmaceuticals was acquired by Aprea Therapeutics, Inc. on May 16, 2022 for $1.33 million. The company's products have the highest known potency for inhibiting ATR and exhibit ATR selectivity with potential broad therapeutic profile. | Health Technology |
Atriva Therapeutics GmbH
Atriva Therapeutics GmbH BiotechnologyHealth Technology Atriva Therapeutics GmbH is a biopharmaceutical company that develops host-targeting antiviral therapies. It focuses on the development of new antiviral therapies against different respiratory viral infections. The company was founded by Rainer Lichtenberger and Henrik Luer Lueßen in April 2015 and is headquartered in Tuebingen, Germany. | Health Technology |
Envisagenics, Inc.
Envisagenics, Inc. BiotechnologyHealth Technology Envisagenics, Inc. engages in developing of artificial intelligence platform for discovering drugs. The company was founded by Maria Luisa Pineda and Martin Akerman and is headquartered in New York, NY. | Health Technology |
